Sleep, Diabetic Retinopathy and Melatonin

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Illinois at Chicago
Study ID
NCT04547439
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Melatonin — DRUG
    Melatonin 3 mg will be taken nightly for 8 weeks
  • Placebo — OTHER
    Placebo will be given nightly for 8 weeks

Study Details

This study explores the use of melatonin in patients with diabetic retinopathy

Key Dates

Start date
Feb 3, 2021
Status verified
Apr 2026
Primary completion
Feb 2, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
42 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Active Comparator: Control
    Placebo
  • Active Comparator: Melatonin
    Melatonin

Primary Outcome Measure

Sleep pattern [ Time Frame: 14 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Illinois at ChicagoChicagoIllinois60612
Sirimon Reutrakul, MD

Find similar trials in Chicago, IL

By condition
Diabetic retinopathy
By specialty
OphthalmologyRetina
By research site
University of Illinois at Chicago· Chicago, IL

Related Studies